AGO1 encodes Argonaute-1, a central component of the microRNA (miRNA)-induced silencing complex (miRISC). Argonaute proteins bind microRNAs and guide them to target messenger RNAs, leading to translational repression or degradation. Beyond miRNA function, AGO1 has miRNA-independent roles in gene regulation and has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This page covers AGO1 structure, function, disease associations, and therapeutic potential.
| Property | Value |
|----------|-------|
| Gene Symbol | AGO1 |
| Full Name | Argonaute-1 |
| Chromosomal Location | 1p34.3 |
| NCBI Gene ID | 26523 |
| OMIM ID | 607294 |
| Ensembl ID | ENSG00000080546 |
| UniProt ID | Q9Y5B9 |
| Encoded Protein | Argonaute-1 |
| Protein Size | 859 amino acids (~97 kDa) |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS, intellectual disability |
¶ Structure and Mechanism
¶ Domain Architecture
Argonaute-1 contains multiple functional domains:
- N-terminal domain: Mediates miRNA loading and target recognition
- PAZ domain (Piwi/Argonaute/Zwille): Binds the 3' end of the miRNA
- MID domain: Binds the 5' phosphate of the miRNA guide strand
- PIWI domain: Endonuclease activity (slicing), structurally similar to RNase H
The PIWI domain can cleave (slice) perfectly complementary targets, though AGO1 primarily mediates translational repression rather than cleavage.
AGO1 loads microRNAs through a structured pathway:
- Pre-miRNA is processed by Dicer to generate ~22 nt miRNA duplex
- One strand (guide) is selected and loaded into AGO1
- The miRNA-AGO complex becomes catalytically active as miRISC
- The miRNA guides AGO1 to targets via base-pairing
AGO1 mediates miRNA-guided gene silencing:
- Translational inhibition (primary mechanism for most miRNAs)
- mRNA destabilization (deadenylation and decay)
- Transcriptional gene silencing in the nucleus (nuclear AGO)
AGO1 is enriched at synapses and regulates:
- Local protein synthesis at dendritic spines
- Synaptic plasticity-related mRNAs
- Activity-dependent dendritic branching
During brain development, AGO1:
- Regulates neuronal differentiation
- Controls axon guidance
- Modulates dendrite morphogenesis
AGO1 dysfunction contributes to AD pathogenesis:
- Altered miRNA profiles in AD brain affect AGO1 function
- AGO1 regulates amyloid precursor protein (APP) and BACE1 mRNAs
- Dysregulated AGO1 affects synaptic protein expression
- Some AGO1 variants modify AD risk
In PD:
- AGO1 regulates LRRK2 and α-synuclein expression
- miRNA-AGO pathways are dysregulated in dopaminergic neurons
- AGO1-mediated silencing of Parkin and PINK1 affects mitophagy
In HD:
- Mutant huntingtin disrupts AGO1 function
- Altered miRNA profiles affect AGO1 loading
- AGO1 dysregulation contributes to transcriptional dysfunction
In ALS:
- Some AGO1 variants increase disease risk
- AGO1 function is altered by TDP-43 pathology
- Dysregulated miRNA-AGO pathways affect motor neuron survival
- He et al., Argonaute and neurodegenerative disease (2024)
- Nelson et al., AGO1 in Alzheimer's disease (2020)
- Zhang et al., microRNA and Argonaute in Parkinson's disease (2019)
AGO1 and associated miRNAs are therapeutic targets:
- miRNA mimics: Restore beneficial miRNA function
- miRNA antagonists (antagomirs): Block harmful miRNAs
- Small molecules: Modulate miRISC loading and function
- Gene therapy: Deliver specific miRNAs to affected brain regions